Featured Press Releases

Moleculin

Moleculin's AML treatment gets EMA's Orphan Drug Designation

TIVDAK® Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

TIVDAK® Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

  • 29 Apr 2024

Genmab A/S announced the U.S. Food and Drug Administration (FDA) has approved the supplemental...

Find Therapeutics announces FDA clearance of its IND application for a Phase 1 study of FTX-101 to treat chronic optic neuropathy

Find Therapeutics announces FDA clearance of its IND application for a Phase 1 study of FTX-101 to treat chronic optic neuropathy

Quantum-Si launches Platinum® Pro, the end-to-end solution for gaining deeper insights in proteomics

Quantum-Si launches Platinum® Pro, the end-to-end solution for gaining deeper insights in proteomics

Eli Lilly’s Foundayo™: The Newest GLP-1 Innovation Offered by Ro

Eli Lilly’s Foundayo™: The Newest GLP-1 Innovation Offered by Ro

Kerri McCullough Wood Named Chief Commercial Officer at Avid Bioservices

Kerri McCullough Wood Named Chief Commercial Officer at Avid Bioservices

Aspera Biomedicines launched its second ADAR1p150 crystallization to the ISS aboard SpaceX CRS-34

Aspera Biomedicines launched its second ADAR1p150 crystallization to the ISS aboard SpaceX CRS-34

  • Aspera Biomedicines Inc.
  • 18 May 2026
Galvanize Therapeutics receives FDA clearance for the Aliya EX Generator, expanding its Aliya Pulsed Electric Field portfolio

Galvanize Therapeutics receives FDA clearance for the Aliya EX Generator, expanding its Aliya Pulsed Electric Field portfolio

  • Galvanize Therapeutics, Inc.
  • 18 May 2026
Peter Menziuso named EVP and President of BD Interventional

Peter Menziuso named EVP and President of BD Interventional

  • BD
  • 18 May 2026
A new real-world case series examines re-induction with ADSTILADRIN in clinical practice

A new real-world case series examines re-induction with ADSTILADRIN in clinical practice

  • Ferring Pharmaceuticals
  • 17 May 2026
Biohack skin longevity with Futurecode Booster

Biohack skin longevity with Futurecode Booster

  • Dermalogica
  • 16 May 2026
ENHERTU received U.S. approval for two new indications in HER2-positive early breast cancer.

ENHERTU received U.S. approval for two new indications in HER2-positive early breast cancer.

  • AstraZeneca
  • 15 May 2026
The Digital Pharma Advances Conference 2026

Most Popular
May   2026
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.